trending Market Intelligence /marketintelligence/en/news-insights/trending/kjrrnyybnm8tbupmyp8mnq2 content esgSubNav
In This List

Zymeworks licenses antibody platforms to Daiichi Sankyo

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Zymeworks licenses antibody platforms to Daiichi Sankyo

Canada's Zymeworks Inc. agreed to license two antibody platforms to Japan's Daiichi Sankyo Co. Ltd.

Under the agreement, Zymeworks will receive US$18 million up front for its Azymetric and Efect platforms, which enable the customization of certain antibody therapies. Daiichi Sankyo also agreed to pay up to US$466.7 million in milestone payments and double-digit tiered royalties on global product sales.

The agreement expands a 2016 cross-licensing and collaboration agreement between the companies.